Shree Cements jumped 5.5 points to 24,458 and formed robust bullish candlestick pattern on the daily charts with robust volumes, continuing uptrend for fourth consecutive session. The stock has seen a break out of long downward sloping resistance trend line adjoining September 15, 2021 and April 29, 2022.

At 12.35 pm, the scrip was trading 8.16 per cent higher at Rs 711 over the last days closing of Rs 657.35 a piece. The stock has declined 43 per cent in the past one year while it has surged over 12 per cent in the last one month.For the quarter ended June 30, 2022

The shares were disposed of at an average price of Rs 615.14 apiece on BSE and Rs 614.79 on NSE, taking the combined transaction value to Rs 36.20 crore.

The company is investing heavily on improving turnaround time and addressing quality perception of the brand in the market through a combination of network expansion, buying new machines, strengthening logistics and cold chain, automation, and ensuring that all of its labs are NABL accredited.

Thyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 3513.57 Crore) operating in Hospitals & Allied Services sector.

The pragmatic strategy would be to stay light on positions and be stock-specific, said Sameet Chavan of Angel One

The company is in early discussions with several global strategic investors and other potential purchasers of the shares, said the people, asking not to be identified because the deliberations arent public. Metropolis, traded in Mumbai with a market value of $1.1 billion -- about half what it was at the start of the year -- tapped Barclays as an adviser, they said.

European stocks rose on Tuesday after a string of upbeat earnings, while banking shares gained as government bond yields hit fresh highs in anticipation of quicker interest rate hikes by global central banks to tackle surging inflation. The pan-European STOXX 600 index climbed 0.6 per cent, rebounding from a "flash crash" in the previous session caused by a single sell order trade by Citigroup Inc.

The company will use Rs 1,929 crore from the IPO proceeds to repay or prepay borrowings and Rs 1,259 crore to fund organic growth initiatives, besides allocating Rs 1,500 crore on inorganic growth opportunities through acquisitions and other strategic initiatives.

Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic.

A graduate of IIM Bangalore, Rahul Guha joins API Group to head its Diagnostics Business. Hehas spent almost 17 years at Boston Consulting Group (BCG) where he has led the health care & life sciences practice.

Thyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 5758.02 Crore) operating in Hospitals & Allied Services sector.

The company launched operations with 11 labs including a 45,000 square feet national reference lab in Navi Mumbai and 200 collection centres in West and East India. The drug maker said it plans to open over 100 labs across and 1000 collection centres across India in the next three years. About 90% of collection centres will be run by franchisees.

“We will not live without fear for a decade if this virus keeps mutating, he says. No need for a booster dose if the virus not mutating, according to him.”

Thyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 6069.19 Crore) operating in Hospitals & Allied Services sector.

Thyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 6215.12 Crore) operating in Hospitals & Allied Services sector.

With 18,050-18,000 as major support zones on the downside, traders can look at building long positions, keeping this support area as a stop loss.

E-pharmacy platform eyes new cash at $5.6 billion valuation; talks with SoftBank fall through

The euphoria is aided by a massive spike in the share prices of already listed entities such as Metropolis Healthcare, Dr Lal Pathlabs, Medinova Diagnostics and Thyrocare.

Pharmeasys parent API Holdings is seeking a valuation of at least $5.6 billion in a new funding round. SoftBank could invest $150 million to $200 million.

API Holdings' Siddharth Shah on whats next for Thyrocare after the PharmEasy deal, APIs existing online drug delivery business, and what he makes of deep-pocketed rivals Reliance and Tata Group. Excerpts from the interview:

The integrated healthcare model started in the 1980s, and has been one of the World Health Organisations (WHO) recommendations. But the evolution of technology-backed integration has opened a plethora of possibilities that disrupts traditional healthcare in many ways.